Stepping out of antiquity: An update on emerging drugs for the treatment of polycythemia vera

References

• Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5(11):366.
   PubMedGoogle Scholar
• Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J clin oncol. 2012;30(33):4098–4103. .
   PubMed Web of Science ®Google Scholar
• Policitemia GIS. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123(9):656–664.
   PubMed Web of Science ®Google Scholar
• Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33. .
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196–e208.
   PubMed Web of Science ®Google Scholar
• Abu Zeinah G, Krichevsky S, Jaber D, et al. Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival. Presented at ASH Annual Meeting December 6–10, 2019. Orlando, FL. Accessed 2021 Jun 11. https://ashpublications.org/blood/article/134/Supplement_1/2942/423552/.
   Google Scholar
• Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J clin oncol. 2005;23(10):2224–2232. .
   PubMed Web of Science ®Google Scholar
• Marchioli R, Vannucchi AM, Barbui T. Treatment target in polycythemia vera. N Engl J Med. 2013;368(16): 1556. 10.1056/NEJMoa1208500.
   PubMedGoogle Scholar
• Tartaglia A, Goldberg J, Berk P, et al. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol. 1986;23(3):172–176.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–124. .
   PubMed Web of Science ®Google Scholar
• Pearson T, Wetherley-Mein G. Vascular occlussive episodes and venous haematocrit in primary proliferative polycythaemia. Lancet. 1978;312(8102):1219–1222.
   Google Scholar
• Berk P, Goldberg J, Donovan P, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol. 1986;23(2):132–143.
   PubMed Web of Science ®Google Scholar
• Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304(8):441–447. .
   PubMed Web of Science ®Google Scholar
• Donovan PB, Kaplan ME, Goldberg JD, et al. Treatment of polycythemia vera with hydroxyurea. Am J Hematol. 1984;17(4):329–334. .
   PubMed Web of Science ®Google Scholar
• Kaplan M, Mack K, Goldberg J, et al. Polycythemia vesa: an update II. Long-term management of polycythemia vesa with hydroxyurea: a progress report. Semin hematol. 1986;23(3):167–171.
   PubMed Web of Science ®Google Scholar
• Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997;34(1):17–23.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132–1137. .
   PubMed Web of Science ®Google Scholar
• Barbui T, Vannucchi AM, Finazzi G, et al. A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: a propensity‐matched study. Am J Hematol. 2017;92(11):1131–1136. .
   PubMed Web of Science ®Google Scholar
• Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica. 2008;93(7):988–993. .
   PubMed Web of Science ®Google Scholar
• Gwer SO, Onyango KO. Prevalence and incidence of congenital anomalies amongst babies born to women with sickle cell disease and exposed to hydroxyurea during pregnancy: a systematic review protocol. JBI Database System Rev Implement Rep. 2018;16(5):1135–1140.
   PubMedGoogle Scholar
• Ballas SK, McCarthy WF, Guo N, et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc. 2009;101(10):1046–1051. .
   PubMed Web of Science ®Google Scholar
• Cantisani C, Kiss N, Naqeshbandi AF, et al. Nonmelanoma skin cancer associated with Hydroxyurea treatment: overview of the literature and our own experience. Dermatol Ther. 2019;32(5):e13043. .
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Chevret S, Dosquet C, et al. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29(29):3907–3913.
   PubMed Web of Science ®Google Scholar
• Bjorkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29(17):2410–2415. .
   PubMed Web of Science ®Google Scholar
• Silver RT. A new treatment for polycythemia vera: recombinant interferon alfa. Blood. 1990;76(4):664–665.
   PubMed Web of Science ®Google Scholar
• Foa P, Massaro P, Ribera S, et al. Role of interferon alpha‐2a in the treatment of polycythemia vera. Am J Hematol. 1995;48(1):55–57. .
   PubMed Web of Science ®Google Scholar
• Sacchi S, Leoni P, Liberati M, et al. A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera. Ann Hematol. 1994;68(5):247–250. .
   PubMed Web of Science ®Google Scholar
• Cimino R, Rametta V, Matera C, et al. Recombinant interferon α‐2b in the treatment of polycythemia vera. Am J Hematol. 1993;44(3):155–157.
   PubMed Web of Science ®Google Scholar
• Turri D, Mitra M, Di Trapani R, et al. Alpha-interferon in polycythemia vera and essential thrombocythemia. Haematologica. 1991;76(1):75–77.
   PubMed Web of Science ®Google Scholar
• Samuelsson J, Hasselbalch H, Bruserud O, et al. A phase II trial of pegylated interferon α‐2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer. 2006;106(11):2397–2405. .
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J clin oncol. 2009;27(32):5418. .
   PubMed Web of Science ®Google Scholar
• Kiladjian -J-J, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112(8):3065–3072. .
   PubMed Web of Science ®Google Scholar
• Kiladjian -J-J, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon α–2a. Blood. 2006;108(6):2037–2040. .
   PubMed Web of Science ®Google Scholar
• Mullally A, Bruedigam C, Poveromo L, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 2013;121(18):3692–3702. .
   PubMed Web of Science ®Google Scholar
• Maze D, Kazi S, Gupta V, et al. Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis. JAMA Network Open. 2019;2(10):e1912666–e. .
   PubMed Web of Science ®Google Scholar
• Yacoub A, Mascarenhas J, Kosiorek H, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134(18):1498–1509. .
   PubMed Web of Science ®Google Scholar
• Mesa RA, Kosiorek HE, Mascarenhas J, et al. Impact on MPN symptoms and quality of life of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia: results of myeloproliferative disorders research consortium (MPD-RC) 112 global phase III trial. Presented at ASH Annual Meeting December 1–4, 2018. San Diego, CA. https://ashpublications.org/blood/article/128/22/4271/113810.
   Google Scholar
• Knudsen TA, Hansen DL, Ocias LF, et al. Long-term efficacy and safety of recombinant interferon alpha-2 vs. hydroxyurea in polycythemia vera: preliminary results from the three-year analysis of the daliah trial-a randomized controlled phase III clinical trial. Blood. 2018;132(Supplement 1):580. .
   Google Scholar
• Abu-Zeinah G, Krichevsky S, Cruz T, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021. https://doi.org/10.1038/s41375-021-01183-8
   Google Scholar
• Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–435. .
   PubMed Web of Science ®Google Scholar
• Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Lancet Oncol. 2017;18(1):88–99. .
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Vannucchi AM, Griesshammer M, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016;101(7):821. .
   PubMed Web of Science ®Google Scholar
• Kiladjian -J-J, Zachee P, Hino M, et al. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol. 2020;7(3):e226–e37. .
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Verstovsek S, Guglielmelli P, et al. Ruxolitinib reduces JAK2 p. V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol. 2017;96(7):1113–1120. .
   PubMed Web of Science ®Google Scholar
• Masciulli A, Ferrari A, Carobbio A, et al. Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2020;4(2):380–386.
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Saydam G, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol. 2018;97(9):1591–1600. .
   PubMed Web of Science ®Google Scholar
• Mesa R, Vannucchi AM, Yacoub A, et al. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF). Br J Haematol. 2017;176(1):76–85. .
   PubMed Web of Science ®Google Scholar
• NCCN.Myeloproliferative Neoplasms (Version 1.2020). 2021 Jun 11. https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf.
   Google Scholar
• Kiladjian -J-J, Guglielmelli P, Griesshammer M, et al. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Ann Hematol. 2018;97(4):617–627. .
   PubMed Web of Science ®Google Scholar
• Eliaçık E, Işık A, Aksu S, et al. Pharmacobiological approach for the clinical development of ruxolitinib in myeloproliferative neoplasms. Turkish J Hematol. 2015;32(2):163.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–1881. .
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363–1369. .
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762–1769. .
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Klade C, Georgiev P, et al. Final results from PROUD-PV a randomized controlled phase 3 trial comparing ropeginterferon alfa-2b to hydroxyurea in polycythemia vera patients. Presented at ASH Annual Meeting December 2, 2016. San Diego, CA. https://ashpublications.org/blood/article/128/22/475/101487.
   Google Scholar
• Gisslinger H, Klade C, Georgiev P, et al. Evidence for superior efficacy and disease modification after three years of prospective randomized controlled treatment of polycythemia vera patients with ropeginterferon alfa-2b vs. HU/BAT. Presented at ASH Annual Meeting December 1–4, 2018. San Diego, CA. https://ashpublications.org/blood/article/132/Supplement%201/579/263449.
   Google Scholar
• Gisslinger H, Klade C, Georgiev P, et al. Long-term use of ropeginterferon alpha-2b in polycythemia vera: 5-year results from a randomized controlled study and its extension. Presented at ASH Annual Meeting 2020; December 7, 2020; Virtual. Accessed 2021 Jun 11. https://ashpublications.org/blood/article/136/Supplement%201/33/470192.
   Google Scholar
• Verger E, Soret-Dulphy J, Maslah N, et al. Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J. 2018;8(10):1–6. .
   PubMedGoogle Scholar
• Nordic. MPN Study Group. Nordic care program for patients with Essential Thrombocythemia, Polycythemia Vera and Primary Myelofibrosis. Accessed on 2021 Jun 11. Available on: https://nmpn.org/index.php/guidelines/17-nmpn-care-program-2017/file; 2017.
   Google Scholar
• Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057–1069. .
   PubMed Web of Science ®Google Scholar
• Barbui T, Vannucchi AM, De Stefano V, et al., Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 8(3): e175–e84. 2021. .
   PubMed Web of Science ®Google Scholar
• Casu C, Nemeth E, Rivella S. Hepcidin agonists as therapeutic tools. Blood. 2018;131(16):1790–1794.
   PubMed Web of Science ®Google Scholar
• **Kremyanskaya M, Ginzburg Y, Kuykendall AT, et al. PTG-300 eliminates the need for therapeutic phlebotomy in both low and high-risk polycythemia vera patients. Presented at ASH Annual Meeting 2020; 2020 Dec 7; Virtual. Accessed June 11, 2021. https://ashpublications.org/blood/article/136/Supplement%201/33/470195.
   Google Scholar
• Taranath R, Bourne G, Zhao L, et al. Regulation of iron homeostasis By PTG-300 improves disease parameters in mouse models for beta-thalassemia and hereditary hemochromatosis. Presented at ASH Annual Meeting December 7–10, 2019. Orlando, FL. https://ashpublications.org/blood/article/134/Supplement_1/3540/428348.
   Google Scholar
• Nakatake M, Monte-Mor B, Debili N, et al. JAK2 V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene. 2012;31(10):1323–1333. .
   PubMed Web of Science ®Google Scholar
• Lu M, Wang X, Li Y, et al. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood J Am Soc Hematol. 2012;120(15):3098–3105.
   Google Scholar
• Lu M, Xia L, Li Y, et al. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells. Blood J Am Soc Hematol. 2014;124(5):771–779.
   Google Scholar
• Mascarenhas J, Lu M, Virtgaym E, et al. Open label phase I study of single agent oral RG7388 (idasanutlin) in patients with polycythemia vera and essential thrombocythemia. Blood. 2017;130(Supplement 1):254.
   Google Scholar
• Mascarenhas J, Higgins B, Anders D, et al. Safety and efficacy of idasanutlin in patients (pts) with hydroxyurea (HU)-resistant/intolerant polycythemia vera (PV): results of an international Phase II study Presented at ASH Annual Meeting 2020; 2020 Dec 7; Virtual. Accessed June 11, 2021. https://ashpublications.org/blood/article/136/Supplement%201/29/470240.
   Google Scholar
• Gotlib J, Gabrail N, O’Connell CL, et al. A randomized, open-label, multicenter, phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of KRT-232 compared with ruxolitinib in patients with phlebotomy-dependent polycythemia vera. Presented at ASH Annual Meeting December 7–10, 2019. Orlando, FL. https://ashpublications.org/blood/article/134/Supplement_1/4168/425756.
   Google Scholar
• Guerini V, Barbui V, Spinelli O, et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2 V617F. Leukemia. 2008;22(4):740–747. .
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150(4):446–455. .
   PubMed Web of Science ®Google Scholar
• Finazzi G, Vannucchi AM, Martinelli V, et al. A phase II study of G ivinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol. 2013;161(5):688–694. .
   PubMed Web of Science ®Google Scholar
• Finazzi G, Iurlo A, Martino B, et al. A long-term safety and efficacy study of givinostat in patients with polycythemia vera: the first 4 years of treatment. Blood. 2017;130(Supplement 1):1648. .
   Google Scholar
• Tremblay D, Mascarenhas J. Novel therapies in polycythemia vera. Curr Hematol Malignancy Rep. 2020;15:1–8.
   PubMed Web of Science ®Google Scholar
• Jutzi JS, Kleppe M, Dias J, et al. LSD1 Inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone. Hemasphere 2018;2(3):3. .
   Web of Science ®Google Scholar
• Bewersdorf JP, Giri S, Wang R, et al. Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis. Leukemia 2021;35(6):1643–1660.
   Google Scholar
• Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015;126(4):560–561. .
   PubMed Web of Science ®Google Scholar
• Ronner L, Podoltsev N, Gotlib J, et al. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020;135(19):1696–1703. .
   PubMed Web of Science ®Google Scholar
• De Stefano V, Za T, Rossi E, et al. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia. Am J Hematol. 2010;85(2):97–100. .
   PubMed Web of Science ®Google Scholar